Pharmaceutical

Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12.

Sep 16, 2024 - 04:00
Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older
Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12.
Read the original article

Tags:

Previous Article

EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity

Next Article

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Once a Silicon Valley darling, Mindstrong sells its mental health technology for parts

STAT+: Once a Silicon Valley darling, Mindstrong sells ...

Mar 22, 2023

WHO recommends second malaria vaccine, hoping to address supply issues

WHO recommends second malaria vaccine, hoping to addres...

Oct 2, 2023

STAT+: Feds fine Medicare Advantage plans for overcharging their members

STAT+: Feds fine Medicare Advantage plans for overcharg...

Aug 29, 2023